Article
Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Gastroenterology - 1 Jun 2008
Nagasaka Takeshi, Koi Minoru, Kloor Matthias, Gebert Johannes, Vilkin Alex, Nishida Naoshi, Shin Sung Kwan, Sasamoto Hiromi, Tanaka Noriaki, Matsubara Nagahide, Boland C Richard, Goel Ajay
Abstract excerpt
BACKGROUND & AIMS: Colorectal cancers (CRCs) with the CpG island methylator phenotype (CIMP) often associate with epigenetic silencing of hMLH1 and an activating mutation in the BRAF gene. However, the current CIMP criteria are ambiguous and often result in an underestimation of CIMP frequencies in CRCs. Because BRAF and KRAS belong to same signaling pathway, we hypothesized that not only mutations in BRAF but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.